

Primary serous papillary peritoneal carcinoma 1

=Abstract=

A Case of Primary Peritoneal Carcinoma

Tae Won Sunwoo, M.D., Chan Lee, M.D.

Department of Obstetrics and Gynecology, College of Medicine, Pochon CHA University, Seoul, Korea

Primary papillary serous carcinomas (PPC) of the peritoneum are very rare and classically present with widespread intraperitoneal dissemination, superficial invasion, and minimal ovarian stromal involvement. Because of clinically and histologically similar to advanced stage epithelial ovarian carcinoma the treatment has been a similar fashion-cytoreductive surgery followed by systemic chemotherapy. Histologic differentiation between papillary mesotheliomas, primary ovarian tumors, borderline tumors of the ovary with peritoneal deposits and primary peritoneal carcinoma may be difficult. The prognosis is very poor and the median lifespan 4 months. We experienced a case of primary peritoneal carcinoma and reported with the brief review of the literature.

Keywords: Primary peritoneal carcinoma, metastasis, poor prognosis

PPC 1

Primary peritoneal serous papillary carcinoma(PPC)

Primary peritoneal serous papillary carcinoma (PPC) is a rare entity. It is characterized by widespread intraperitoneal dissemination, superficial invasion, and minimal ovarian stromal involvement. The prognosis is very poor and the median lifespan 4 months. We experienced a case of primary peritoneal carcinoma and reported with the brief review of the literature.

가 1990 New South Wales 5% 4 6
1) 6.7
15% 가 .23) : G2, P2, A0
57 4 가 :
. PPC : 15 ,
가 : 가
가 : CA

125 188 U/ml, CEA <0.5 ng/ml, -FP 4.7 ng/ml
CA 125 >500 U/ml

3.5 × 3 × 2 cm

diverticula

30 × 15 × 3 cm

PH 7.5, 67
/μL, 9100 /μL, 5.7 g/ml
4%, 96%

2) :
psammoma body가
(Fig. 1).

가

(Fig. 2).

가

5 cm

가

가

OC 125, AE

Vimentin, Desmin, Actin, S-100,

가

4 cm

가

2 cm

7
가 2

가

가

Fig. 1. The multiple Psammoma body in glandular structure of primary serous papillary adenocarcinoma.

가

psammoma body가
가

1) : 7.5 × 6 × 5 cm
110 gm
2.0 cm

Fig. 2. The metastatic lesion on ovarian surface of primary serous papillary adenocarcinoma with sarcomatous component.

3) : Swerdlow primary peri-
 (1) Histology of left ovary had shown papillary toneal papillary serous carcinoma .
 serous adenocarcinoma of peritoneum PPC
 (2) Both parametrium and omentum had metastatic
 carcinoma
 (3) Myometrium had a interstitial leiomyoma and . 57 .6)
 focal hematogenous spread of tumor cells and psam- 4 cm
 moma body 가
 (4) Cervix had chronic cervicitis and squamous serous papillary adenocarcinoma가
 metaplasia .
 (5) Endometrium was shown proliferative phase and 가 serous papi-
 reddened endometrium llary adenocarcinoma
 : 가
 Percutaneous transhepatic duct tube 400 가
 ml Parmley Woodruff .
 . 7)
 Gitsch Keratin Vimentin
 Helix
 가
 가 .8)
 Taxol CDDP
 CEA, CA 125, CA 19-9
 2 . PPC Bollinger
 S-100 28 3
 9)
 S-100 PPC
 B72.3
 Primary peritoneal papillary serous carcinoma BerEP4
 Swerdlow 1959 PPC S-100, B72.3,
 , , BerEP4 3가 2 가
 가 papillary serous , 3
 carcinoma(PPC) 1 CA125
 (mesothelioma) 가 가 3 가
 .4) Foyle (malignant peri-
 toneal mesothelioma) PPC 가
 5) papillary
 serous carcinoma 가 . PPC peritoneal meso-
 . extraovarian thelioma
 serous papillary carcinoma 가

PPC .12) cisplatin

ma . PPC ovarian serous papillary carcino- 31 29 . Stranad
, PPC 18 cisplatin 23
, , , 41 , 59 ,
.10) 가 77 .13)

(adhesive . Della
properties) type I collagen vitronectin 가 가
matrix metalloproteinases
(MMP)-2, MMP-9, urinary-type plasminogen
activator matrix-degrading proteinases signet ring 가
. PPC 가
matrix (multiple .14) Wall platinum
extracellular matrix proteins) 15
type I collagen coated surfaces 24 paclitaxol(420 mg/m2) 3
2 가
. Andrew 4
paclitaxel cisplatin
1 3
가 가
.15) Steven 46
cisplatin-doxorubicin-cyclophosphamide(PAC) pacli-
taxel-cisplatin (TP)
가 16)
rdance PPC .
PPC p53 17
34 18% 100%
P53 wild type p53 .
.11)
p53 12.4
22.5 2
PPC .
1997 11
. Fromm 74
50% cisplatin 1
63.6% .
(median survival rate) 24

- References -

1. Coates M, McCredie M, Taylor R: Cancer in New South Wales: Incidence and mortality. NSW Cancer Council Registry 1990.
2. Stewart JF, Tattersall MHN, Woods RL, Fox RM: Unknown primary adenocarcinoma: Incidence of overinvestigation and natural history. *BMJ* 1979;1:1530-33.
3. Moertel CG, Reitemeier RJ, Schutt AJ, Hahn RG: Treatment of the patient with adenocarcinoma of unknown origin. *Cancer* 1972;20:1469-72.
4. Swerdlow M: Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary. *Am J Obstet Gynecol* 1959;77:197-200.
5. Foyle A, Al-Jabi M, McCaughey WT: Papillary peritoneal tumors of women. *Am J Surg Pathol* 1981;5: 241-9.
6. David AF, Krishna C, M Sharon Stack: Biochemical Characterization of Primary Peritoneal Carcinoma Cell Adhesion, Migration, and Proteinase Activity. *Gynecol Oncol* 1997;67:193-9.
7. Parmley TH, Woodruff JD: The ovarian mesothelioma. *Am J Obstet Gynecol* 1974;32:297-302.
8. G Gitsch, U Tabery, W Feigl, G Breiteneker: The differential diagnosis of primary peritoneal papillary tumors. *Arch Gynecol Obstet* 1992;251:139-44.
9. Bollinger DJ, Wick MR, Dehner LP, Mills SE, Swanson PE, Clarke RE: Peritoneal malignant mesothelioma versus papillary adenocarcinoma. *Am J Surg Pathol* 1989;13:659-70.
10. Ute M Moll, Fidel Valea, John Chumas: Role of p53 Alteration in primary Peritoneal Carcinoma. *International J of Gynecology Pathology* 1997;16:156-62.
11. Fromm GL, Gershenson DM, Silva EG: Papillary serous carcinoma of the peritoneum. *Obstet Gynecol* 1990;75: 89-95.
12. Stranad CM, Grosh WW, Baxter J: Peritoneal carcinomatosis of unknown primary site in women. A distinct subset of adenocarcinoma. *Ann. Int. Med* 1989; 111:213-7.
13. Della-Fiorentina SA, Jaworski RC, Crandon AJ, Harnett PR: Primary peritoneal carcinoma: a treatable subset of patients with adenocarcinoma of unknown primary. *Aust. N. Z. J Surg* 1996;66:124-5.
14. Andrew W Menzin, James K Aikins Jr, James E Wheeler, Stephen C Rubin: Surgically Documented Responses to Paclitaxel and Cisplatin in Patients with Primary Peritoneal Carcinoma. *Gynecol Oncol* 1996;62:55-8.
15. M Steven Piver, Gamal H LLtabbakh, Ronald E Hemling, Fernando O Recio, Leslie E Blumenson: Two Sequential Studies for Primary Peritoneal Carcinoma: Induction with Weekly Cisplatin Followed by either Cisplatin-Doxorubicin-Cyclophosphamide or Paclitaxel-Cisplatin. *Gynecol Oncol* 1997;67:141-6.